Melanomas are highly variable with respect to aberrant gene expression and chromosomal lesions but share a common characteristic of an acquired independence from environmental growth factors that are needed for proliferation of normal melanocytes. This autonomy is achieved in part via the endogenous production of basic fibroblast growth factor (bFGF), which is not expressed in normal melanocytes. Other melanocyte mitogens such as acidic FGF (aFGF), K-FGF/hst, FGF-5 and FGF-6, are not expressed in melanomas, in spite of the presence of amplified K-FGF/int-2 linked genes in one out of ten melanomas. These other mitogens may however, have a role in promoting the growth of melanomas at site of metastasis since some of them are known to be produced in normal tissues. The bFGF receptor is a tyrosine protein kinase that is constitutively active in melanomas. Blocking of the tyrosine-kinase activity by antagonists, antibodies or low molecular weight inhibitors, retards melanoma growth in culture, suggesting new directions for drug design for the clinical management of metastatic melanomas. comparative influence of such cell interactions on tumour behaviour has not been thoroughly investigated from the perspective of diffeent stages of tumour progression. Specifically, we wished to determine whether the nature and effects of such cell interactions would vary between metastatically-competent vs incompetent tumour cell populations. To address this question we assessed the influence of normal dermal fibroblasts on the growth of human melanoma cells obtained from different stages of tumour progression. We found that the in vitro growth of most (four out of five) melanoma cell lines derived from early stage metastatically-incompetent primary lesions is repressed by coculture with normal dermal fibroblasts, suggesting that negative homeostatic growth controls are still operative on melanoma cells from early stages of disease. On the other hand, nine out of 11 melanoma cell lines derived from advanced metastatically competent primary lesions, or from distant metastases, were found to be growth stimulated in the presence of dermal fibroblasts. This discriminatory fibroblastic influence is mediated by soluble inhibitory and stimulatory growth factor(s) whose nature could not be identified by using neutralising antibodies directed against known growth factors. Taken together, these results indicate that fibroblast-derived signals can have antithetical effects on metastatic vs metastatically-incompetent tumour subpopulations. This resultant conversion in responsiveness may confer upon metastatic cells a growth advantage allowing them to escape local growth controls both locally and at distant ectopic tissue sites. Metastatic potential in cutaneous melanoma first appears with the onset of the vertical growth phase and the probability of developing metastatic disease increases with increasing vertical thickness of the tumour. Searching for changes in gene expression which correlate with increasing tUmour thickness, may lead to the identification of molecules which are involved in the metastatic process. We isolated two monoclonal antibodies which reacted with more than 70% of thick primary melanomas, but which showed no reactivity with melanocytic nevi or with thin radial growth phase primary tumours. The cDNAs encoding these antigens were obtained by antibody screening of expression libraries. Sequencing of the cDNA clones revealed that one antigen was the intercellular adhesion molecule ICAM-1 which mediates adhesion with leukocytes. The second antigen, MUC18, is a novel member of the immunoglobulin superfamily and has structural characteristics of a cell adhesion molecule. Alterations in intercellular adhesion are thought to play a major role in the metastatic process and the role of these two molecules in the interaction of melanoma cells with other cells and tissues is being examined. The results of chemotherapy for advanced melanoma are disappointing. The most active single agents are: dacarbazine (DTIC) which has a response rate of 24%, and vindesine, cisplatin and nitrosoureas which all have response rates of about 15%. Response durations are short, 4-6 months and complete remissions to single agent therapy rare. Randomised studies of DTIC -containing combinations or combinations without DTIC do not suggest any advantage over single agent DTIC. Response rates of almost 50% have been reported in some more recent phase II studies using DTICor cisplatin -containing regimens, but randomised trials are needed to properly evaluate these new schedules. Recently, there has been considerable interest in the observation that when tamoxifen is added to a combination of cisplatin, DTIC and BCNU the response rate is doubled. One of the major difficulties in interpreting the results of chemotherapy in melanoma is that different sites of disease show different rates of response: lymph node, skin or soft tissue metastases are the most responsive (34%) followed by the lungs (16%) and finally the brain and liver (8%). The same regimen may therefore have a very different response rate depending on the proportion of patients that have a visceral element to their metastatic disease. There is no evidence that chemotherapy is of any benefit when given in the adjuvant setting to patients at high risk from relapse from melanoma. Future studies are likely to involve the integration of chemotherapy with biological response modifiers such as interferon and interleukin-2 and these approaches are already showing promise. Clin. Oncol., 7, 477, 1989) . These early studies used the maximum tolerated doses of IL-2 and were associated with severe toxicity in some patients requiring ICU facilities. The use of continuous infusion or intermittent i.v. bolus IL-2 therapy has allowed similar total doses to be delivered as by the Rosenberg group but with much less toxicity and similar antimelanoma activity (West et al., New Engl. J. Med., 316, 898, 1987; Thatcher et al., Br. J. Cancer., 60, 770, 1989 In order to validate the efficacy of our materials prior to treating minimal residual disease, we have treated patients with measurable disseminated melanoma, with active specific immunotherapy. Mechanical lysates of two cell lines of melanoma were combined with the adjuvant DETOX and injected s.c. on weeks 1, 2, 3, 4 and 6 into nearly 100 patients in six separate trials. A major response. rate of 20% has been achieved, with 5% complete remissions. Another 10% of the patients have had minor responses: (25-50% shrinkage for >4 week or >50% shrinkage lasting <4 weeks). Complete or partial remissions have been seen in subcutaneous sites, lymph nodes, lungs, and small intestine, with 33% shrinkage of a large liver nodule in one patient and disappearance of a 1.5 cm liver nodule (cyst?) in another. Thus far, seven patients have had continuing responses lasting 1 to > 4 years, on 'maintenance' immunotherapy. One patient with a primary ocular melanoma has also been treated. The lesion shrank from 4.2 to 2.3 mm within 6 weeks and has remained that size for > 6 months. No toxicity was associated with this treatment, except local granulomas in patients receiving 15 or more injections. The frequency of cytolytic T cell precursors has been increased in responders, whereas patients without an increase invariably have failed to respond. Both CD4 + and CD8 + cytolytic T cell clones have been grown from treated patients. Most CD4 + CTL were not Class II MHC restricted, reacting broadly against melanoma cell lines but not other types of tumour. Several of the clones in fact reacted against melanomas lacking Class II MHC antigens. Some CD8 + CTL were self-MHC restricted, as in mice, but more usually recognised melanoma antigens presented by the HLA-A2 molecule on several cell lines. The HLA phenotypes of responders and non-responders were compared. Although it might seem the surgical extirpation of bladder cancer should be followed by a very good survival rate, the facts are that this is not necessarily so. Superficial bladder cancers, 'completely' removed by surgical methods, have about a 75% 5-year survival rate. Invasive bladder cancers, 'completely' removed by radical excision have about a 35% 5-year survival rate. Thus it is evident that surgery, at best, can only be part of an overall management strategy. Because superficial bladder cancer is a multifocal disease, most cases require additional treatment in the hope of preventing recurrence and arresting progression. The management of invasive bladder cancer remains a frustration because methods for detecting distant spread are crude. Where selection methods are optimum then the results of monotherapy may be improved, to a degree, but overall the management of invasive bladder cancer should now incorporate one of the combinations -surgery/radiotherapy/chemotherapy. Protagonists of radiotherapy have a long history in UK urology based mainly on the hope that preservation of the bladder could be achieved by radiotherapy alone in a high proportion of cases. A widening range of surgical techniques have led to a reappraisal as to whether preservation of the bladder, at all costs, is now justified. Chemotherapy now has an established role in the management of metastatic transitional cell carcinoma (TCC) and a potential role in the management of locally advanced (T3, T4) disease. The active chemotherapy drugs cisplatin (C), methotrexate (M), vinblastine (V), and adriamycin (A), will, when used as single agents, cause partial regression (PR) in approximately 15-30% of patients; complete remission (CR) is however unusual. Initial (though small) randomised trials have suggested no additional benefit from the use of drug combinations. In recent years newer drug combinations have however been devised e.g. CMV and MVAC, which have been reported as being more effective. This presentation will discuss the present role of such drug combinations and the management of this disease emphasising the results of randomised clinical trials, and will detail present and proposed studies in the UK. The confirmation that long term durable complete remission can be achieved in greater than 50% of patients with BCG is increasingly recognised as evidence for the relevance of immunological response in control of this tumour. Further evidence in support for this concept will be presented in this talk which will review results from this department demonstrating that there is a direct relationship between degree of loss of HLA class I antigen expression and degree of tumour invasion as well as the lack of induction of tumour infiltrating lymphocytes by culture of tumour cell suspensions with Interleukin-2, suggesting that there may be advantage in combining BCG with other cytokines that augment HLA antigen expression. Results Tyrosine, the rate-limiting enzyme for melanin synthesis, is a key phenotypic marker of melanocyte differentiation. In order to understand better the functions and regulation of tyrosinase, cell lines expressing tyrosinase in the absence of all other components of the melanin synthesis pathway have been established. Mouse 3T3 Swiss fibroblasts, which do not normally synthesise melanin, were co-transfected by calcium phosphate precipitation with a G418 resistance marker and a mouse tyrosinase expression vector, pHDmcTyrl (Muller et al. (1988) . EMBO J., 7, 2723). Of 63 clones isolated, four are brown in colour, presumably due to synthesis of melanin. Karyological studies of one clone confirm that it is direct derivative of the 3T3 Swiss line although there is a significantly larger number of chromosome fusions in the transferred cells. The brown clones express both activities of tyrosinase -tyrosine hydroxylase activity and dopa oxidase activity -whereas the parent mouse fibroblasts do not. This confirms that one enzyme, encoded by the cDNA mcTyrl, has both activities of tyrosinase. Expression of the protein cannot be detected by Western blot analysis of crude cell extracts using the anti-tyrosinase monoclonal antibodies 2G10 or TMH-1. Tyrosinase is known to be expressed at a low level in normal melanocytes (0.01% of total protein) and the level in transfected cells is probably too low to be detected by this method. These clones should prove to be extremely useful in the study of many properties of mouse tyrosinase, including cofactor requirement, post-translational modification, and targeting to melanosomes. Understanding the regulation of this enzyme should provide a starting point for the elucidation of the mechanism of melanocyte differentiation. N-(2-Hydroxypropylmethacrylamide) (HPMA) copolymers containing doxorubicin (DOX) or melphalan (ME) show considerable efficacy against many tumours in vivo. Here we have investigated the effect of liver-targeted and tumourtargeted drugs on establishment of hepatic metastases in melanoma-bearing mice. Copolymers were synthesised to contain ME or DOX (7.6 and 6.9 wt% of drug, respectively). Liver-targeting was achieved by inclusion of galactosamine (4.1 mol%) (delivery of the conjugates selectively to hepatocytes) and tumour-specific targeting was promoted by incorporation of melanocyte-stimulating hormone (MSH 5.0 mol%). The molecular weight of the conjugates was approximately 19 kD, polydispersity < 1.4. B16.FIO melanoma cells (5 x 105) were inoculated into the spleens of male C57 mice. To optimise targeting efficiency all drugs and drugconjugates were administered twice daily (I.P, days 1 to 10) at a dose of 0.5mg drugkg-' body weight. When salinetreated animals became sick (days 11-12) all mice were killed and hepatic tumour-invasion was assessed visually and quantified by assay of melanin. MEL, as free drug, untargeted or targeted conjugate, showed little inhibition of tumour metastasis and liver-invasion. DOX, known to be more active against B16.F10 cells in vitro, also displayed better efficacy in vivo. Free DOX decreased hepatic invasion from 30.2 ± 10.3% (control) to 10.2 ± 6.0%. Untargeted HPMA copolymer-DOX (10.8 ± 3.2%) and galactose-targeted HPMA copolymer-DOX (10.5 ± 5.0%) gave similar efficacy.
Best was MSH-HPMA copolymer-DOX, which reduced invasion to 2.0 ± 1.0%. We conclude that tumour-specific DOX-targeting is more effective than untargeted or organspecific therapy in the prevention of liver metastasis of B16 In a phase II clinical study, six patients (pts): four male, two female, median age 60 years, with metastatic melanoma, completed therapy with DTIC and interleukin-2 (IL-2). This comprised: DTIC at 250 mg m2 IV x 5 days and IL-2 at 3 x 106 U m-2 24 h-' given as two 5-day IV infusions starting 16 days after DTIC. After a 1-week gap, at least one further course was given. Major responses were seen in two (33%) pts, both female, aged 60 and 65, who achieved complete and partial remission (CR, PR), respectively. Both remain free of progression at > 7 months after therapy. One additional pt remains well with stable disease at > 7 months.
Three pts are dead of progressive melanoma. Five other pts with melanoma: three female, two male, median age 44, received r-IFN-a 2a at 3 x 106 U m 2 by subcutaneous injection x 5 days, followed by IL-2, as above. This was repeated at least once, after a 16-day gap. All pts suffered progressive disease and four have died. Nine pts with metastatic renal cell carcinoma (RCC): five male, four female, median age 55, received IL-2 alone, as described above. At least three cycles at 16-day intervals, were given. There were no major responses, but 2 pts remain well with stable disease at >2 months from therapy. Two pts have died of RCC. Treatment was well tolerated although the one pt with melanoma, who attained PR, developed hypothyroidism. Twelve pts have been monitored for immune responses. All developed augmented natural killer (NK) and lymphokine-activated killer (LAK) cell activity. Increased lymphocyte proliferation was invariable and, in the 2nd week of each cycle, eosinophilia developed. IL-2 did not stimulate the production of tumour necrosis factor (TNF) although in one pt with RCC and bony involvement, there was evidence of enhanced endogenous production of TNF. Production of soluble IL-2 receptors was observed and IL-6 production was stimulated in the 2nd week of IL-2 therapy. While there was no clear correlation between clinical response and bio-immunological activity, the highest levels of IL-6 were observed in the one, female pt with melanoma, who achieved CR. These high levels have been maintained during the current period in which she remains free of detectable relapse. Many monoclonal antibodies prepared by immunisation with bladder cancer cell lines, do not appear to recognise primary bladder tumour tissue. Our aim was to produce a specific antibody to transitional cell carcinoma (TCC) using primary tumour as an immunogen. Balb/c mice were immunised with a disaggregated primary bladder tumour on two occasions followed by boosting with a second tumour 4 days prior to fusion with P3NSI. We have produced an antibody 977 3B2 which stained six to nine bladder tumours and none of five normal bladders so far tested by immunohistology. 977 3B2 binds to cytoplasmic granules and cell membrane, and reacts with antigens expressed upon the bladder cell line RT1 12, but not the cell lines Colo 205 or 791T. By immunohistology the determinant has not been identified in a variety of normal tissues. The reactivity of 977 3B2 with tissue specimens (normal and malignant including non TCC tumours) is presently under extensive investigation. The in vivo labelling of urological tumour cells using the S phase marker bromodeoxyuridine (BRdU) has been reported. The use of multiparameter flow cytometry (FCM) with BRdU labelling to study tumour proliferation provides simultaneous measurements of the DNA ploidy (DI), the duration of the S phase (Ts), the potential doubling time (Tpot) and the total and aneuploid tumour labelling indices (LI) from a single specimen. Heterogenous tumour cell populations can be measured with high sensitivity. We report a study to evaluate the method in the measurement of the kinetics of transitional cell carcinoma of the bladder (TCCB). Eleven patients with a proven TCCB consented to receive a bolus dose of 250 mg BRdU 3-6 h prior to endoscopic tumour resection. Multiparameter FCM analysis of ethanol preserved tissue was performed using propidium iodide to measure DNA content and a monoclonal antibody to detect BRdU incorporated into S phase nuclei. One tumour was aneuploid, DI = 1.89. The remainder were diploid. BRdU uptake was detected in all tumours. The median LI was 2.5%, range 0.3-4.6%. In 7/11 tumours the profile was satisfactory for calculation of the Ts and Tpot. The mean Ts was 6.0 h (range 3.5-9.7) and the mean Tpot was 25.8 days (range 5.3-64.8 Recent studies have suggested that altered expression of the p53 gene is a common abnormality in colo-rectal and lung cancer and increased amounts of epidermal growth factor receptor protein (EGFr) are found in locally advanced bladder cancer. We recently described altered expression of c-erbB-2 in bladder cancer and have carried out this study to determined the relationship between these three oncoproteins. Expression of the p53, EGFr and c-erbB-2 protein was studied in 82 patients with primary bladder cancer using an immunohistochemical method. Strong staining was found in 17% of tumours for p53, in 15% for c-erbB-2 and in 30% for the EGFr. Tumours invading bladder muscle were more likely to be positively stained for p53 and EGFr compared with superficial tumours. No association was found between p53 and EGFr expression, but there was a positive correlation between the expression of c-erbB-2 and p53. No association was found between muscle invasive tumours and increased expression of c-erbB-2. Analysis of DNA by Southern transfer hybridisation revealed one case of c-erbB-2 gene amplification from 27 samples examined. This tumour was one of the two strongest positively staining samples in the immunohistochemistry series. Elevated levels of c-erbB-2 transcripts were detected in four out of 50 RNA samples screened. Alteration in the expression of p53, EGFr and c-erbB-2 were found frequently in human transitional cell carcinoma of the urinary bladder and may be of clinical use in defining patients with differing prognosis. We have already shown that a significant proportion of bladder cancers overexpress the epidermal growth factor receptor protein (EGFr). Both EGF and Transforming Growth Factor-alpha (TGF-a) are known ligands for the EGFr. Evidence suggests that EGF has an exocrine function with high levels in body fluids, whereas TGF-a may be more important at tissue level where it could function through either autocrine or paracrine mechanisms. We have determined the levels of EGF and TGF-x in 47 bladder specimens (including 40 bladder tumours) by radioimmunoassay. EGFr content was also determined using a radioligand binding assay. Significantly higher levels of TGF-a (Mean ± s.d.
8.47 ± 9.81 ng gm-') were detected compared with EGF (0.82 ± 0.94 ng gm-1). In addition, higher levels of TGF-a were detected in malignant (9.50 10.26 ng gm') compared with non-malignant tissue (2.60 2.49 ng gm-). There did not appear to be any correlation between ligand level and EGFr content or between ligand level and tumour stage or grade. The previously reported association of EGFr content and tumour stage and grade was again evident. These results strengthen the argument in favour of TGF-a being the more important ligand at tissue level. Whether high TGF-a levels have a significant impact on the biological behaviour of these tumours will be determined by clinical follow up. Though previously considered to be a marker of the extremely rare chorioepithelioma of the bladder, immunoreactive hCG-like material can be detected in serum in 30% of bladder patients. It has been shown in vitro that seven of nine bladder tumours and four of five urothelial cell lines secrete hCG-like material into their culture media (Iles et al., 1987) . Immunochemical analysis showed that this material consisted almost entirely of free a-subunit (Iles & Chard, 1989) . Serum and early morning urine samples from 175 patients, with various stages of bladder disease, were assayed for hCG using a P-subunit, directed RIA. Forty-six patients showed elevated levels. Elevated levels of serum immunoreactive P-hCG was detected in 16 of 21 patients (76%) with confirmed metastases, but only two of 64 patients (3%) with disease limited to the pelvis. In urine elevated P-hCG levels were detected in 14 of 57 TA/I cases (25%), 11 of 25 T2/T4 cases (71%) and five of seven metastatic disease patients (71%) . Immunochemical analysis of samples from this study showed that only one of seven metastatic patients and one of 21 patients with disease limited to the bladder, produced intact hCG. Since only the intact hCG a-P hetrodimer is biologically active; this explains the discrepancy between the high incidence of immunoreactive hCG expression by bladder tumours and the rarity of gonadotrophin associated clinical endocrinopathies (Iles et al., 1990) .
